Loading...
•
Dec 31, 2024
GoodRx Q4 2024 Earnings Report
Financial results for the fourth quarter and full year of 2024 were released.
Key Takeaways
GoodRx reported Q4 2024 revenue of $198.6 million and net income of $6.7 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.
Revenue of $198.6 million
Net income of $6.7 million; Net income margin of 3.4%
Adjusted Net Income of $34.7 million; Adjusted Net Income Margin of 17.5%
Adjusted EBITDA of $67.1 million; Adjusted EBITDA Margin of 33.8%
Revenue by Segment
Forward Guidance
For the first quarter and full year 2025, management is anticipating revenue of $201 - $205 million for Q1 2025, and $810 - $840 million for FY 2025. Adjusted EBITDA Margin is anticipated to be ~33% for Q1 2025 and Adjusted EBITDA of $270 - $286 million for FY 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...